Wells Fargo analyst Jim Birchenough maintained a Hold rating on Jounce Therapeutics Inc (NASDAQ: JNCE) today and set a price target of $10. The company’s shares closed on Friday at $11.23, close to its 52-week low of $10.21.
According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 25.6% and a 51.8% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Voyager Therapeutics Inc, and Bellicum Pharmaceuticals.
Currently, the analyst consensus on Jounce Therapeutics Inc is Moderate Buy and the average price target is $16.33, representing a 45.4% upside.
In a report released today, J.P. Morgan also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.25 and a one-year low of $10.21. Currently, Jounce Therapeutics Inc has an average volume of 567.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat catcer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
Read More on JNCE:
